EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EpCAM + Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

Byeonggeol Mun iD, Jinyoung Kim iD, Chang Gon Kim iD, Seokhyeong Go, Mina Han, Yujin Ouck, Soojin Jang, Seong Uk Son, Gamin Kim iD, Wonrak Son, Eunjung Kim iD, Min Hee Hong iD und 4 weitere

Advanced Science · 2026-09 · 13 (54)

DOI: 10.1002/advs.76389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.07.2026. Verfasst von Byeonggeol Mun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, College of Engineering, Yonsei University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: B7-H1 Antigen, Epithelial Cell Adhesion Molecule, Extracellular Vesicles, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT (MSIT), Ministry of Trade, Industry and Energy, Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death‐ligand 1 (PD‐L1) blockade improves outcomes in patients with various malignancies; however, biomarkers for monitoring treatment responses are lacking. This study presents a surface‐enhanced Raman scattering (SERS)‐based platform for the ultrasensitive detection of PD‐L1 on circulating epithelial cell adhesion molecule‐positive (EpCAM + ) extracellular vesicles (EVs). The platform is validated using interferon‐gamma‐treated epithelial tumor cell line‐derived EVs. The platform is further applied to paired pre‐ and post‐treatment plasma samples from patients with non‐small‐cell lung cancer ( n = 140) and head and neck squamous cell carcinoma ( n = 73) receiving anti‐PD‐(L)1 immunotherapy. Dynamic changes in PD‐L1 expression on EV are shown to correlate with clinical outcomes. A post‐treatment decrease in PD‐L1 expression on EpCAM + EVs (EpCAM + EV PD‐L1) is associated with improved 5‐year progression‐free and overall survival. These results establish EpCAM + EV PD‐L1 as a dynamic, non‐invasive biomarker for monitoring immunotherapy responses and demonstrate the utility of SERS‐based profiling in predicting long‐term responses to immune checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenEpithelial Cell Adhesion MoleculeExtracellular VesiclesBiomarkers, TumorImmune Checkpoint InhibitorsLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansCell Line, TumorFemaleMale

Stichwörter der Autor:innen

EpCAM‐positive extracellular vesicleshead and neck squamous cell carcinomasimmune checkpoint blockadesliquid biopsiesnon‐small‐cell lung cancersprogrammed death‐ligand 1surface‐enhanced Raman scattering

Substanzen

B7-H1 AntigenEpithelial Cell Adhesion MoleculeBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsEPCAM protein, human

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, College of Engineering, Yonsei University, Seoul, Republic of Korea.
  • Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Nanobiotechnology, KRIBB School of Biotechnology, University of Science and Technology, Daejeon, Republic of Korea.
  • Department of Bioengineering and Nano-Bioengineering, Research Center for Bio Materials and Process Development, Incheon National University, Incheon, Republic of Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

ORCID-Profile: Byeonggeol Mun, Jinyoung Kim, Chang Gon Kim, Gamin Kim, Eunjung Kim, Min Hee Hong, Eun-Kyung Lim, Hye Ryun Kim, Seungjoo Haam

Förderung

  • Ministry of Science and ICT (MSIT)
  • Ministry of Trade, Industry and Energy
  • Ministry of Food and Drug Safety
  • Ministry of Health and Welfare
  • KRIBB Research Initiative Program
  • Yonsei University College of Medicine
  • Ministry of Education
  • Korea Medical Institute research program

Zitieren

APA

Mun, B., Kim, J., Kim, C. G., Go, S., Han, M., Ouck, Y., Jang, S., Son, S. U., Kim, G., Son, W., Kim, E., Hong, M. H., Yeo, J. H., Lim, E. K., Kim, H. R., & Haam, S. (2026). EpCAM + Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response. Advanced Science, 13(54). https://doi.org/10.1002/advs.76389

Vancouver

Mun B, Kim J, Kim CG, Go S, Han M, Ouck Y, et al. EpCAM + Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response. Advanced Science. 2026;13(54). doi:10.1002/advs.76389

BibTeX
@article{Mun2026,
  author = {Mun, Byeonggeol and Kim, Jinyoung and Kim, Chang Gon and Go, Seokhyeong and Han, Mina and Ouck, Yujin and Jang, Soojin and Son, Seong Uk and Kim, Gamin and Son, Wonrak and Kim, Eunjung and Hong, Min Hee and Yeo, Ja Hyun and Lim, Eun-Kyung and Kim, Hye Ryun and Haam, Seungjoo},
  title = {EpCAM + Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {54},
  doi = {10.1002/advs.76389}
}
Kostenlos starten →